Fragment-based design of isoquinoline derivatives as anti-inflammatory drugs

Dr Masakazu Atobe and his colleagues have developed a methodology that can be applied to the discovery of effective drugs.

Fragment-based drug discovery (FBDD) is a well-established high-throughput screening method for drug generation. Fragment molecules used in FBDD tend to be structurally less complex than the compounds used in conventional high-throughput screening techniques. Dr Masakazu Atobe from Asahi Kasei Pharma Corporation in Japan and his colleagues have developed a methodology that can be applied to the discovery of effective drugs […]

Read More…

The role of CD83: Autoimmunity, transplantation and beyond

The role of CD83: Autoimmunity, transplantation and beyond

Professor Alexander Steinkasserer is based at the Department of Immune Modulation, University Hospital, Erlangen. His research interests are focused on the immune system, with the long-term aim to develop new therapeutic strategies for patients suffering from autoimmune disorders or in need of transplantation. Along with his colleagues at the department of Immune Modulation, Professor Steinkasserer has shed much light on […]

Read More…

Case for the improvement of suboptimal care of gout patients in Hawai’i

Case for the improvement of suboptimal care of gout patients in Hawai’i

The level of care for gout patients in Hawai’i has been a subject of concern to stakeholders. A retrospective study of gout and rheumatoid arthritis patients who were 18 years and above within Hawai’i Pacific Health healthcare system between 2011 and 2017 were undertaken by Dr Sian Yik Lim MD, CCD, Rhmsus, a Doctor of Medicine, Pali Momi Medical Center, […]

Read More…

Therapeutic drug monitoring of methotrexate in disease

Therapeutic drug monitoring of methotrexate in disease

Professor Dr Robert de Jonge, Dr Gerrit Jansen, Ittai Muller MSc and Helen Gosselt MSc, Amsterdam University Medical Center, are pioneering analytical approaches which can be used to understand why patients respond differently to the anchor drug used to manage rheumatoid arthritis, called methotrexate. Their work has begun to unravel the key factors behind the mechanism of action of methotrexate, […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at audience@researchoutreach.org at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION